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Vasopressin induces phosphorylation of the
thiazide-sensitive sodium chloride cotransporter
in the distal convoluted tubule
Nis B. Pedersen1, Marlene V. Hofmeister1, Lena L. Rosenbaek1, Jakob Nielsen1 and Robert A. Fenton1
1The Water and Salt Research Center, Department of Anatomy, Aarhus University, Aarhus C, Denmark
The thiazide-sensitive Naþ–Cl cotransporter (NCC) is impor-
tant for renal electrolyte balance and its phosphorylation
causes an increase in its transport activity and cellular
localization. Here, we generated phospho-specific antibodies
against two conserved N-terminal phosphorylation sites
(Thr53, Thr58 and Thr53/Thr58) to assess the role of arginine
vasopressin (AVP) in regulating NCC in rodent kidney in vivo.
Immunohistochemistry showed distinct staining of
phosphorylated NCC (pNCC) at the apical plasma membrane
domain of distal convoluted tubule (DCT) cells. Unlike total
NCC, pNCC was localized only to the apical plasma
membrane as determined by immunogold electron
microscopy. In AVP-deficient Brattleboro rats, acute deamino-
Cys-1, d-Arg-8 vasopressin (dDAVP) exposure significantly
increased pNCC abundance at the apical plasma membrane
by about threefold, whereas total NCC and its cellular
distribution were not affected. dDAVP significantly increased
the abundance of phosphorylated STE20/SPS1-related
proline–alanine-rich kinase and oxidative stress-response
kinase (SPAK and OSR1), kinases implicated in NCC
phosphorylation. Intracellular calcium levels in early and late
DCTs were increased in response to 1min superfusion of
dDAVP, confirming that these segments are AVP responsive.
In rats fed a high-salt diet with angiotensin (ANG) type
1-receptor blockade, similar increases in pNCC and active
SPAK and OSR1 were detected following chronic or acute
dDAVP, thus indicating the effects of AVP are independent
of ANGII. Our results show that AVP is a potent regulator
of NCC activity.
Kidney International (2010) 78, 160–169; doi:10.1038/ki.2010.130;
published online 5 May 2010
KEYWORDS: cell and transport physiology; distal tubule; Na-Cl cotransporter;
vasopressin
The thiazide-sensitive Naþ–Cl cotransporter (NCC) loca-
lizes to the distal convoluted tubule (DCT) and is a key
regulator of renal electrolyte balance. Chronic treatment with
aldosterone increases NCC abundance,1 as do other varia-
tions in the renin–angiotensin–aldosterone system such as
those observed during NaCl restriction.2,3 In addition,
angiotensin II (ANGII) has been shown to increase NCC
abundance in the apical plasma membrane of the DCT by
trafficking of NCC from the subapical vesicles; this occurs
without changes in whole-cell total NCC abundance.4
Recently, focus has been given to the role of phospho-
rylation of NCC and its superfamily Slc12 homologues,
the Naþ–Kþ–Cl cotransporters NKCC1 and NKCC2, in
regulating transporter function. All Slc12 family members
contain three conserved threonine (or serine, depending on
species) residues at their N terminus.5 In NCC, phosphor-
ylation of these residues can occur through the WNK-STE20
(sterile 20)-like kinases SPAK (STE20/SPS1-related proli-
ne–alanine-rich kinase) and OSR1 (oxidative stress-respon-
sive kinase-1) pathway, resulting in increased NCC at the cell
membrane and increased cotransporter activity.6–8 Functional
studies in Xenopus oocytes have shown that mutation of T53,
T58, and S71 (mouse and rat nomenclature) decreases NCC
activity, but does not affect the localization of NCC at the cell
membrane.9,10 ANGII can signal through the WNK-SPAK/
OSR1 pathway to activate NCC by phosphorylation at T55
(corresponding to T53 in mouse).11 Furthermore, adminis-
tration of either a low-NaCl or a low-potassium diet results
in increased phosphorylation at all three sites in vivo,8,12
suggesting that changes in the aldosterone and/or ANGII axis
can modulate NCC activity, a process that may be mediated
by the serum and glucocorticoid inducible kinase 1 (ref. 13).
Arginine vasopressin (AVP) is mainly known for its
antidiuretic properties, which occur primarily through its
water-retaining action on the collecting duct, increasing
aquaporin-2 (AQP-2) abundance, phosphorylation, and
membrane targeting.14 Chronic AVP exposure increases
sodium uptake through NKCC2 in the thick ascending
limb (TAL), the abundance of the epithelial Naþ channel in
the collecting duct), and total NCC abundance.15–17 Further-
more, the type 2 vasopressin receptor has been detected in
the DCT, and micropuncture studies have shown that
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deamino-Cys-1, d-Arg-8 vasopressin (dDAVP) increases
NaCl absorption in the DCT.18,19
In this paper, we examine the regulation of NCC
phosphorylation and cellular distribution by AVP using
novel phosphospecific antibodies. We show that phosphory-
lated NCC (pNCC) is localized exclusively at the apical
plasma membrane of DCT cells, where its abundance can be
increased by both acute and chronic AVP stimulation. The
increased pNCC induced by AVP is still apparent during
suppression of aldosterone/ANGII levels and angiotensin
type 1 (AT1)-receptor blockade, indicating that the AVP
effect on NCC is not occurring through activation of the
renin–angiotensin system. We also show that the effects of
AVP observed in our animal models could be mediated by the
WNK-SPAK/OSR1 pathway.
RESULTS
Cellular and subcellular distribution of pNCC
The tubular distribution of pNCC was determined by
immunohistochemistry of normal rat and mouse kidney
sections. In both species, pNCC labeling was observed within
DCT cells (Figure 1). In all labeled tubules, staining was
exclusively associated with the apical plasma membrane of
DCT cells. The anti-pT53- and anti-pT58-NCC antibodies
solely labeled DCT, whereas, when used at higher concentra-
tions, the anti-pT53/pT58-NCC antibody showed a strong
labeling of DCT (Figure 2i-k) and very weak labeling of
TAL segments (Figure 2k and l). Dotblot experiments were
initially performed to determine specificity for each of the
antibodies to its intended pNCC form (Supplementary
Figure 1). However, to show that for immunohistochemistry,
and at the concentration used in our studies, each pNCC
antibody was specific, we performed a number of immuno-
labeling controls. Pre-absorption of each pNCC antibody
with a synthetic phosphopeptide corresponding to the
targeted phosphorylation site completely abolished labeling
(Figure 2c, h and l). In contrast, pre-absorption with either a
synthetic non-phosphorylated peptide (Figure 2b, f, j and k)
corresponding to the same region or a non-targeted pNCC
phosphopeptide (Figure 2d and g) did not affect the pNCC
labeling. The weak labeling of TAL with the anti-pT53/pT58-
NCC antibody was not blocked with pre-incubation using
the corresponding phosphopeptide (Figure 2l), suggesting
nonspecific labeling of this segment. This weak labeling can
most likely be explained by the high primary sequence
homology between NCC and the TAL-expressed NKCC2 in
the region corresponding to the immunogenic peptide used
in the antibody production. Taken together, our results
indicate that the staining of the apical plasma membrane
observed in the rat and mouse DCT is specific for pNCC.
Double immunofluorescence labeling with pNCC anti-
bodies combined (representative image shown for pT53-
NCC in Figure 3a and b) or for pNCC with total NCC
(representative image shown for pT53-NCC and total NCC
in Figure 3c) showed complete co-localization between the
labeling in all DCT cells. This indicates that, at the resolution
of confocal microscopy, pNCC is distributed similarly to total
NCC (see later). No co-localization of pNCC with the TAL
marker Tamm-Horsfall protein was observed (Figure 3d).
Double labeling with the DCT2 and connecting tubule
marker calbindin (Figure 3e) showed partial tubular co-
localization with pNCC as expected, with some segments
labeled only with either calbindin or pNCC alone. In
contrast, labeling with the connecting tubule and collecting
duct principal cell marker AQP-2 showed no co-localization
between pNCC and AQP-2. Taken together, these results
indicate that all pNCC forms are restricted to the DCT (with
greater abundance in the early compared with late DCT), and
that there is no difference in subcellular distribution between
alternative phosphoforms.
Immunogold electron microscopy of normal Wistar rat
kidney revealed that pNCC and total NCC had a different
subcellular distribution in DCT cells. As shown previously,
we observed total NCC in both the apical plasma membrane
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Figure 1 |Novel phosphospecific Naþ–Cl cotransporter (NCC) antibodies label the distal convoluted tubule (DCT) in the rat and
mouse kidney. (a–c) Show anti-pT53-NCC in rat DCT, but not in the late thick ascending limb (TAL) at macula densa (MD) (a) nor in
connecting tubule (CNT) (c). Similar labeling was found for the anti-pT58-NCC and the anti-pT53/pT58-NCC. Panels d–f document a similar
labeling pattern in the mouse kidney for the anti-pT58-NCC. G, glomerulus.
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and in a population of vesicles located in the apical regions of
the cell (Figure 4a and b). In contrast, pNCC labeling was
restricted to the apical plasma membrane, with no staining of
intracellular vesicles (Figure 4c–f). At high magnification, it is
clear that pNCC resides within the plasma membrane, with
gold particles in direct association with the double lipid
bilayer. This pattern of labeling was observed in DCT cells
with many or few microvilli.
Effect of vasopressin on pNCC abundance and distribution
AVP-deficient Brattleboro rats were treated for either 15 or
60 min with the V2 receptor-selective vasopressin analog
dDAVP to determine the effects of short-term AVP treatment
on pNCC abundance. Semiquantitative immunoblotting on
whole kidney homogenates showed that pNCC abundance
was significantly increased in response to dDAVP treatment
(Figure 5). pT53-NCC abundance increased approximately
fourfold, whereas pT58- and pT53/pT58-NCC abundance
increased two to threefold in response to dDAVP treatment.
For all phosphoforms, maximum AVP effects were observed
after 15 min, with no further increase in phosphorylation
observed at the later time point. No significant difference in
total NCC abundance was observed under these conditions
(Figure 5). The results of the immunoblotting were
confirmed using immunohistochemistry on corresponding
Brattleboro rat kidney sections. In vehicle-treated animals,
modest pNCC labeling was apparent in some DCT cells
(Supplementary Figure 2), whereas after dDAVP treatment,
pNCC labeling increased greatly throughout the DCT. At the
resolution of light microscopy, the large increase in pNCC
labeling occurred only at the apical plasma membrane
domain (Supplementary Figure 2 inserts).
To confirm that AVP does not alter the subcellular
distribution of pNCC, immunogold electron microscopy of
Brattleboro rat kidney sections was performed. Acute dDAVP
treatment (60 min) increased the total number of gold
particles in the apical plasma membrane (qualitative
observation), but had no effect on pNCC distribution, with
all phosphorylated forms restricted to the apical plasma
membrane of DCT cells (Figure 6). Quantitative analysis
showed that 68±4.7 (s.e.m) % of total NCC labeling was
associated with the apical plasma membrane under control
conditions (Figure 7). Acute dDAVP treatment had no
significant effect on total NCC abundance in the plasma
membrane (76±3.4 (s.e.m) %). These data suggest that AVP
does not cause a redistribution of NCC and that the large
increase in pNCC in the plasma membrane is due to direct
phosphorylation of transporters already present in the
membrane.
Recent studies have outlined a role for ANGII in
regulating NCC phosphorylation. To eliminate a possible
influence of ANGII and/or aldosterone on the AVP-mediated
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Figure 2 | Specificity of phosphorylated Naþ–Cl cotransporter (pNCC) antibodies. The pNCC antibodies show distinct staining of distal
convoluted tubule (DCT) segments (a, e, and i). Pre-absorption of each pNCC antibody with a synthetic phosphopeptide corresponding
to the targeted phosphorylation site completely abolished labeling (c, h, and l). In contrast, pre-absorption with either a synthetic
non-phosphorylated peptide (b, f, j, and k) corresponding to the same region or a non-targeted pNCC phosphopeptide (d and g) did not
affect pNCC labeling. The weak labeling of cTAL with the anti-pT53/pT58-NCC antibody was not blocked with the T53/T58-phosphopeptide
(l). G, glomerulus; MD, macula densa; TAL, thick ascending limb.
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upregulation of pNCC, we performed both acute and long-
term dDAVP treatment on rats that were fed a high-salt
diet for 4 days to lower their plasma aldosterone and
ANGII levels in addition to blocking the AT1-receptor
(AT1-R) with candesartan. Immunoblotting showed that
both acute (60 min) and chronic dDAVP exposure increased
pNCC three- to five-fold compared with candesartan-
treatment alone, whereas total NCC abundance was not
significantly different between the groups (Figure 8). In
similar to all our other studies, this increase was only
apparent at the apical plasma membrane (Supplementary
Figure 3). These studies suggest that ANGII has no role in the
AVP-mediated upregulation of pNCC.
Vasopressin signaling through the WNK-SPAK/OSR1 pathway
As recent studies suggest that ANGII signals through
the WNK-SPAK/OSR1 pathway to phosphorylate NCC,11
we examined whether the same pathway could have a role
in AVP-mediated NCC phosphorylation. No significant
increases in the total protein abundance of SPAK or
OSR1 (assessment of SPAK/OSR-1 was performed using
antibodies generated independently by two different groups
(see methods). Similar results were obtained using both sets
of antibodies.) were observed after dDAVP exposure in
Brattleboro rats on a normal-salt diet (Figure 9), or Wistar
rats fed a high-salt diet alongside AT1-R blockade (Figure 10).
In contrast, small but significant increase in the active forms
of these kinases, pT240-SPAK/pT185-OSR1 (numbers based
on rat amino acid sequence) or pS380-SPAK/pS325-OSR1,
were observed (when normalized to total kinase abundance)
after either dDAVP treatment in Brattleboro rats (Figure 9)
or Wistar rats (Figure 10). These results indicate that the
WNK-SPAK/OSR1 pathway is a possible mediator of AVP
actions on pNCC abundance in the DCT.
Early and Late DCT respond to dDAVP by increasing
intracellular Ca2þ
DCT1 and DCT2 tubules were identified using a combina-
tion of differential interference contrast and enhanced green
fluorescent protein fluorescence.20 Tubules were loaded with
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Figure 3 | Laser scanning confocal microscopy of phosphorylated Naþ–Cl cotransporter (pNCC) with tubule segment-specific
markers. (a) Biotinylated anti-pT53-NCC shows perfect co-localization with anti-pT58-NCC, (b) biotinylated anti-pT53-NCC shows perfect
co-localization with anti-pT53/pT58-NCC, (c) biotinylated anti-pT53-NCC co-localizes with total NCC, (d) anti-pT53-NCC does not co-localize
with the TAL-specific marker Tamm-Horsfall protein (THP), (e) anti-pT53-NCC partially co-localizes with the DCT2 and connecting tubule
(CNT)-specific marker Calbindin and (f) anti-pT53-NCC does not co-localize with the CNT and collecting duct (CD) marker aquaporin-2
(AQP-2). DCT, distal convoluted tubule; TAL, thick ascending limb. Scale-bar: 10 mm for a–c and 20mm for d–f.
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fluo 4-AM and superfused with HEPES buffer at 37 1C as
indicated below the traces (Figure 11). DCT1 and DCT2/
connecting tubule cells responded to superfusion with
dDAVP (2 10–10 mol/l) by a transient increase in their
intracellular Ca2þ concentration ([Ca2þ ]i).
DISCUSSION
Aldosterone and/or ANGII and vasopressin (AVP) actions on
the kidney are crucial for the maintenance of sodium and
water balance and for the control of blood volume and blood
pressure. Although often considered to act independently,
synergism between adrenal steroid hormones and AVP have
been well documented21–24 suggesting common aldosterone-
and AVP-dependent signaling pathways exist in the renal
tubule. In the aldosterone-sensitive distal nephron, NCC
function in the DCT is essential for normal NaCl home-
ostasis; as highlighted by the use of thiazide diuretics or the
phenotype of patients with Gitelmann’s syndrome.25,26
Although the actions of the renin–angiotensin–aldosterone
system on NCC abundance have been well documented,1–3
Total NCC pT53 NCC pT58 NCC
Figure 4 | Immunogold electron microscopy of normal rat kidney sections shows that phosphorylated Naþ–Cl cotransporter
(pNCC) is present only in the apical plasma membrane. In kidney sections from Wistar rats, immunogold electron microscopy shows that
total NCC (a and b) is detected in the apical plasma membrane (arrows) and subapical vesicles (arrowheads). In contrast, both pT53-NCC
(c and d) and pT58-NCC (e and f) were localized to the apical plasma membrane alone (arrows). Gold particle diameter¼ 10 nm.
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Figure 5 |Phosphorylation of Naþ–Cl cotransporter (NCC) increases with acute deamino-Cys-1, d-Arg-8 vasopressin (dDAVP)
treatment in vivo. Immunoblotting with anti-pT53-NCC, anti-pT58-NCC, anti-pT53/pT58-NCC and total NCC antibodies on whole kidney
homogenates from Brattleboro rats treated intravenously with either saline () or dDAVP (þ ) for 15 or 60min. Representative immunoblots
for the 60min treatment are shown. Data are band densities relative to control (mean±s.e.), n¼ 4. *Po0.05 from control, #Po0.01 between
15 and 60min dDAVP. AU, arbitrary units.
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little is understood about AVP’s actions on NCC. Recent
studies have shown an essential role of N-terminal phos-
phorylation on the activity and localization of NCC and its
Slc12-superfamily cotransporter members.7,9,27 In this study
we show that AVP is a potent regulator of pNCC in vivo.
Our results clearly show that pNCC is confined to the
apical plasma membrane of cells throughout the DCT. No
difference was observed in the distribution of the different
pNCC forms, suggesting that NCC phosphorylation on
different residues occurs in the same cellular compartment;
most likely while in direct association with the plasma
membrane. The confinement of pNCC to the apical plasma
membrane is in contrast to the distribution of total NCC. As
we show here at the electron microscopy level, and as shown
previously,3,4 total NCC is detected in both the apical plasma
membrane and in a population of vesicles located in the
apical regions of the cell. The identity of these vesicles is not
known, and unfortunately we have previously been unsuc-
cessful in double immunogold labeling using markers for
both early and recyling endosomes (R.A. Fenton, unpub-
lished observation). Recent reports have shown in vitro that
mutating T53 and/or T58 and thus preventing phosphoryla-
tion decreases NCC transport activity induced by chloride
depletion, but does not affect membrane localization of
NCC.9,10 Together with our present results, this suggests that
NCC phosphorylation is required for full transporter activity,
but not for membrane targeting. This is in contrast to, for
example, the water channel AQP-2 that is targeted to and
retained in the apical plasma membrane after phosphoryla-
tion, but whose channel activity is not directly affected.28–30
There are contrasting reports as to whether the type 2
vasopressin receptor is localized in the DCT, with some
investigators reporting both type 2 vasopressin receptor
mRNA and protein in this segment31,32 but not others.33
Our studies clearly show that both the early and late DCT
respond to dDAVP by increasing intracellular Ca2þ , and
classical studies have also shown that the DCT can increase
intracellular cAMP levels in response to AVP (reviewed by
Morel et al.34). Our finding that AVP can regulate pNCC
abundance provides a molecular explanation for previous
micropuncture studies, which showed that NaCl absorption
in the DCT can be regulated by dDAVP.18,19 Acute dDAVP
treatment of Brattleboro rats resulted in a large increase in
pNCC abundance, but did not induce a significant cellular
redistribution of either pNCC or total NCC. Rather, AVP
increased pNCC abundance directly within the apical plasma
pT53 con pT58 con
pT53 dDAVP pT58 dDAVP
Figure 6 | Immunogold labeling of phosphorylated Naþ–Cl
cotransporter (pNCC) in Brattleboro rat kidney sections after
acute deamino-Cys-1, d-Arg-8 vasopressin (dDAVP)
treatment. Brattleboro rats treated intravenously with either
saline or dDAVP (60min) and kidney sections subjected to
immunogold electron microscopy. Under control conditions
(a and c), weak pNCC labeling was observed in the apical plasma
membrane. After dDAVP treatment (b and d), pNCC increased
only in the apical plasma membrane. No gold particles were
observed inside the cell. Gold particle diameter¼ 10 nm. Control
N
dDAVP
Figure 7 | Immunogold labeling of total Naþ–Cl
cotransporter (NCC) in Brattleboro rat kidney sections
after acute deamino-Cys-1, d-Arg-8 vasopressin (dDAVP)
treatment. Brattleboro rats treated intravenously with either
saline or dDAVP (60min) and kidney sections subjected to
immunogold electron microscopy. Under control conditions (a),
total NCC labeling was observed in the apical plasma membrane
(arrows) and also in intracellular vesicles (arrowheads). After
dDAVP treatment (b), no significant difference in the number
of gold particles associated with the apical plasma membrane
was observed. Gold particle diameter¼ 10 nm.
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membrane. This suggests that dDAVP acutely modifies the
activity of NCC that is already present in the plasma
membrane and does not induce NCC trafficking. The effects
of dDAVP on pNCC are in contrast to the previously
reported effects of ANGII on NCC distribution. In elegant
studies by Sandberg et al.,4 acute ANGII treatment provoked
rapid trafficking of NCC from subapical vesicles to the
plasma membrane. Whether acute ANGII can regulate NCC
phosphorylation in vivo will likely be a focus of future
studies.
Recent studies have shown that pNCC abundance can be
increased by a low-NaCl or a low-potassium diet,8,12
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Figure 10 |pSPAK/OSR1 increase in rats fed a high-salt diet alongside AT1-receptor blockade following either acute or chronic
deamino-Cys-1, d-Arg-8 vasopressin (dDAVP) treatment. (a) Immunoblotting with total SPAK/OSR1 or active, phosphorylated
SPAK/OSR1 of kidney homogenates from Munich-Wistar rats treated subcutaneously with either candesartan, candesartanþdDAVP for
4 days, or candesartan plus acute dDAVP (60min). (b) Graphs show summarized data. Data are band densities relative to total kinase
abundance (mean±s.e.), n¼ 5. *Po0.05 from candesartan, #Po0.05 between chronic dDAVP and acute dDAVP. AU, arbitrary units.
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suggesting a role of the renin–angiotensin–aldosterone system
in modulating NCC activity. Our studies using a high-salt
diet (to lower ANGII and/or aldosterone) and candesartan
(to block the AT1-R) indicate that both the chronic and acute
effects of AVP can occur independently of aldosterone/ANGII
effects. Future studies examining synergistic actions of
AVP and aldosterone/ANGII on pNCC abundance will be
informative and may help explain previous functional
observations.24
Physiologically, the effects of AVP on regulating pNCC
abundance, and presumably activity, are a conundrum. As
the DCT is relatively water impermeable under normal
conditions, NaCl reabsorption along the DCT contributes to
urinary dilution, with maximal urinary dilution occurring
when AVP levels are low. However, our studies show that
high AVP levels result in greater NCC phosphorylation and
presumably greater NaCl reabsorption as previously shown
by micropuncture.18,19 There are no obvious explanations for
these seemingly opposing effects, but one could speculate
there may be a situation where AVP-induced increases in
NaCl reabsorption in the DCT are able to increase the
osmotic gradient for AVP-induced water absorption from
neighboring connecting tubules and cortical collecting ducts.
Mathematical modeling may be informative in this respect.
Increased phosphorylation of the kinases SPAK/OSR1 by
WNK1 has shown to increase pNCC abundance, resulting in
increased co-transporter activity.7 Furthermore, it has been
recently shown that ANGII signaling in Xenopus oocytes
increases NCC activity by abrogating WNK40s inhibition
of NCC.11 This effect is mediated by the AT1-R and is
dependent on SPAK activation. In our study, we observed an
effect of dDAVP on increasing the active phosphorylated
forms of the kinases, pT240-SPAK (pT185-OSR1) and
pS380-SPAK (pS325-OSR1). Thus, the strong positive effect
of AVP on pNCC abundance is likely to be mediated by a
WNK-SPAK/OSR1 pathway, although whether dDAVP-in-
duced increases in cAMP or intracellular Ca2þ are respon-
sible remains unresolved.
MATERIALS AND METHODS
Materials
Affinity-purified rabbit polyclonal antibodies (anti-pT53-, anti-
pT58-, and anti-pT53/pT58-NCC) were generated against proprie-
tary sequences from the N terminus of rat NCC that included pT53,
pT58, or both (PhosphoSolutions, Aurora, CA, USA). In addition to
the new antibodies, a total AQP-2 antibody against the N terminus
of AQP-2 (N-20, Santa Cruz, Santa Cruz, CA, USA), a goat poly-
clonal antibody against Tamm-Horsfall protein (G-20): sc-19554,
Santa Cruz), a mouse monoclonal antibody against calbindin D-28K
(Research Diagnostics, Acton, MA, USA) and a rabbit polyclonal
antibody against total NCC1 were used.35 For detection of SPAK/
OSR1, a combination of three sheep polyclonal antibodies against
total SPAK, pT240-SPAK (pT185-OSR1), and pS380-SPAK (pS325-
OSR1)36 and two additional rabbit polyclonal antibodies against
total SPAK and pS380-SPAK37 were used (nomenclature based on
rat amino-acid sequence). These antibodies have been used to detect
SPAK/OSR1 in mammalian cells, in oocytes and in vivo. Although
the pT240-SPAK antibody raised in sheep should recognize both
pOSR1 and pSPAK, as the target sequences are identical, in our
study this antibody preferentially detected pT240-SPAK (on the
basis of molecular weight). In contrast, the rabbit polyclonal
pS380-SPAK (pS325-OSR1) preferentially detected pOSR1 and not
pSPAK (on the basis of molecular weight), similar to as observed
previously.38 Although the results using both sets of antibodies were
similar, all immunoblots depicted in this article contain images
using the sheep pT240-SPAK antibody36 and rabbit total SPAK and
pS380-SPAK.37
Animal studies
All animal protocols were approved by the boards of the Institute of
Anatomy and Institute of Clinical Medicine (University of Aarhus)
in accordance to the licenses for the use of experimental animals
issued by the Danish Ministry of Justice.
Protocol 1. Munich-Wistar rats were maintained on standard
rodent diet with free access to water. Following anesthesia with
isoflurane, the left kidney was perfusion fixed with 3% paraformal-
dehyde in 0.1 M sodium cacodylate, pH 7.4 through the abdominal
aorta. Kidneys were removed, postfixed for 60 min in 3%
paraformaldehyde in 0.1 M sodium cacodylate and tissue prepared
as described below. Kidneys from C57/BL6J mice were prepared for
epoxy sections as previously described.39
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Figure 11 | Effect of deamino-Cys-1, d-Arg-8 vasopressin
(dDAVP) on intracellular Ca2þ ([Ca2þ ]i). Enzymatically isolated
renal tubules were plated on coverslips, and a differential
interference contrast image (inset) and enhanced green
fluorescent protein fluorescence signal (not shown) were
acquired. The cells were loaded with the intracellular Ca2þ -
sensitive dye fluo-4. Representative traces show the fluo-4 signal
from 5 cells (yellow, red; late distal convoluted tubule (DCT)/
connecting tubule and light blue, green, dark blue; early DCT),
indicated in the differential interference contrast image. The
experimental procedure of measuring [Ca2þ ]i was (1) baseline
recording in HEPES-buffered salt solution; (2) addition of dDAVP
(2 10–10 M) to the superfusate, as indicated; and (3) clamp of
[Ca2þ ]i to extracellular Ca
2þ concentration ([Ca2þ ]e) by
ionomycin (2 10–6 M) in normal Ca2þ (1.8 10–3 M) buffer and in
a Ca2þ -free buffer containing EGTA (1 10–3 M). Data are
normalized to initial fluo-4 signal. All segments of the DCT
respond to dDAVP. G, glomerulus.
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Protocol 2. Short-term dDAVP infusion of Brattleboro
rats. Homozygous Brattleboro rats deficient in AVP were treated
with intravenous injection of 1 ng dDAVP in 200 ml saline per
animal, and eight saline-injected rats served as controls. The rats
were anesthetized after 15 or 60 min (four rats for each group), the
right kidney removed for protein preparation and the left kidney
perfusion fixed as described above. Between injection of dDAVP and
fixation of the kidney, the 60-min group had free access to water but
not food. The 15-min group was kept under anesthesia.
Protocol 3. Acute and chronic dDAVP treatment of
Munich-Wistar rats after AT1-R blockade with candesartan. Male
rats were maintained on a standard rodent diet. During the
experiment, rats were housed in metabolic cages and received a
high-salt diet equivalent of 2.0 mEq Naþ per 200 g body weight per
day. Animals had free access to water. Rats were randomly divided
into three groups (five animals per group) and osmotic minipumps
(Alzet, Cupertino, CA, USA, model 2001) were surgically implanted
subcutaneously to deliver for 4 days; Group 1, the AT1-R blocker cande-
sartan (1 mg per kg per day; AstraZeneca, Mo¨lndal, Sweden) dissolved
in 0.02 M Na2CO3 in physiological saline; Group 2, candesartan plus
10 ng/h dDAVP (Sigma-Aldrich, St Louis, MO, USA); Group 3, cande-
sartan followed by an intramuscular injection of dDAVP (10 ng in 100ml
saline) 60 min before perfusion fixation. The dose of candesartan has
been shown to be sufficient to block the rise in blood pressure resulting
from long-term infusion of ANGII.40 Kidneys were prepared for
immunoblotting and for immunohistochemistry.
Immunoblotting
Tissue processing and semiquantitative immunoblotting was per-
formed as previously described33 using affinity-purified anti-pT53-,
anti-pT58-, and anti-pT53/pT58-NCC. Equal quantities of total
protein were loaded per lane as determined by Coomassie blue
staining (Supplementary Figure 4). Band densities in the immuno-
blotting experiments were calculated as relative abundance ratios
(treated vs control) for each individual sample for each time point.
Values are mean±s.e. Analysis of variance followed by unpaired
t-tests were used for statistical comparisons as appropriate. P-values
o0.05 were considered to be statistically significant.
Immunohistochemistry
Preparation of tissue for light and confocal microscopy. All
procedures have been described in detail previously.33 Labeling was
visualized by the use of a peroxidase-conjugated secondary antibody
for light microscopy (P448, Dako, Copenhagen, Denmark) and
Alexa 488, 546, or 555-conjugated secondary antibodies of either
donkey or goat origin for confocal microscopy. For double labeling
with antibodies derived from the same host species, one of the
antibodies was biotinylated (Pierce, Rockford, IL, USA) and
subsequently detected with Alexa546-conjugated streptavidin.33
Pre-incubation experiments. Affinity-purified anti-pT53, anti-
pT58, and anti-pT53/pT58-NCC were pre-incubated at 4 1C over-
night with 10 times molar excess of peptide. Peptides were equal to
the immunogenic peptide used for antibody synthesis, with or
without phosphorylation on T53 and/or T58.
Immunogold electron microscopy and quantitation. All
tissue processing, staining, and counting procedures have been
described in detail previously.3 Briefly, for quantitiation,
four dDAVP (60 min) and four saline-treated controls were
observed, with a minimum of five cells per animal analyzed
from sections oriented approximately at right angles to the apical
cell membrane and showing negligible background over mitochon-
dria and nuclei.
Renal tubule isolation and measurement of intracellular Ca2þ
levels. All procedures have been described in detail previously.20
Where possible, tubules with a glomerulus attached were used for
the analysis to aid in identification of the DCT1 segments. dDAVP
was used at 2 1010 M and ionomycin was used at 2106 M
(Sigma).
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SUPPLEMENTARY MATERIAL
Figure S1. Dot blots to demonstrate specificity of the pNCC
antibodies.
Figure S2. Immunoperoxidase labeling of phosphorylated NCC in
renal cortex of Brattleboro rats.
Figure S3. The acute and chronic effects of dDAVP on increasing
pNCC are independent from the effects of ANGII.
Figure S4. Coomassie blue stained gels demonstrate equal total
protein abundances and loading for all samples.
Supplementary material is linked to the online version of the paper at
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